Dr. Porter on the 3-Year Follow-Up Data From the CheckMate-9LA Trial in NSCLC

Supplements And Featured Publications, The Current and Future State of Immune Checkpoint Inhibitors in NSCLC, Volume 01, Issue 01

Jason Porter, MD, discusses the 3-year follow-up data from the phase 3 CheckMate-9LA trial done in patients with metastatic non–small cell lung cancer.

Jason Porter, MD, medical oncologist, hematologist, director, Lung Cancer Disease Research Group, West Cancer Center and Research Institute, discusses the 3-year follow-up data from the phase 3 CheckMate-9LA trial (NCT03215706) done in patients with metastatic non–small cell lung cancer (NSCLC).

CheckMate-9LA evaluated nivolumab (Opdivo) and ipilimumab (Yervoy) plus chemotherapy vs chemotherapy alone as a first-line treatment for patients with metastatic NSCLC.

The 3-year follow-up data showed encouraging survival benefits with the addition of nivolumab and ipilimumab to chemotherapy, irrespective of patients’ histology or PD-L1 status, Porter says. The 3-year overall survival (OS) rates for patients who received the combination therapy vs chemotherapy alone were 27% and 19%, respectively, Porter adds. Moreover, patients with PD-L1–negative disease who were treated with combination therapy achieved a 3-year OS rate of 25% vs 15% in those who received chemotherapy alone, Porter explains.

Additionally, patients with a PD-L1 expression of at least 1% who received nivolumab/ipilimumab plus chemotherapy experienced a 3-year OS rate of 28% compared with 19% in those who received chemotherapy alone, Porter emphasizes.

Patients who have symptomatic disease or greater disease burden will typically need chemotherapy, Porter adds. Improving outcomes in these patients with only 2 cycles of chemotherapy in CheckMate-9LA is an exciting development, Porter concludes.